{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T19:22:59Z","timestamp":1793733779698,"version":"4.6.1"},"reference-count":73,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,22]],"date-time":"2022-11-22T00:00:00Z","timestamp":1669075200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.critrevonc.2022.103886","type":"journal-article","created":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T08:00:49Z","timestamp":1669276849000},"page":"103886","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"special_numbering":"C","title":["Drug-based therapy for advanced adenoid cystic carcinoma: Current landscape and challenges based on an overview of registered clinical trials"],"prefix":"10.1016","volume":"181","author":[{"given":"Vivian Petersen","family":"Wagner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renata","family":"Ferrarotto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo Agustin","family":"Vargas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manoela Domingues","family":"Martins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colin D.","family":"Bingle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynne","family":"Bingle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2022.103886_bib1","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.scr.2017.04.003","article-title":"Unlocking the chromatin of adenoid cystic carcinomas using HDAC inhibitors sensitize cancer stem cells to cisplatin and induces tumor senescence","volume":"21","author":"Almeida","year":"2017","journal-title":"Stem Cell Res."},{"key":"10.1016\/j.critrevonc.2022.103886_bib2","first-page":"7","volume":"126","author":"Andreasen","year":"2018"},{"issue":"15","key":"10.1016\/j.critrevonc.2022.103886_bib3","doi-asserted-by":"crossref","first-page":"3374","DOI":"10.1002\/cncr.25852","article-title":"A phase 2 trial of bortezomib followed by the addition of doxorubicin at progression in patients with recurrent or metastatic adenoid cystic carcinoma of the head and neck: a trial of the Eastern Cooperative Oncology Group (E1303)","volume":"117","author":"Argiris","year":"2011","journal-title":"Cancer"},{"issue":"12","key":"10.1016\/j.critrevonc.2022.103886_bib4","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1016\/j.oraloncology.2015.10.002","article-title":"Salivary adenoid cystic carcinoma in Denmark 1990-2005: outcome and independent prognostic factors including the benefit of radiotherapy. Results of the Danish Head and Neck Cancer Group (DAHANCA)","volume":"51","author":"Bj\u00f8rndal","year":"2015","journal-title":"Oral Oncol."},{"issue":"5","key":"10.1016\/j.critrevonc.2022.103886_bib5","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1080\/08880010701316850","article-title":"Adolescent and young adult (AYA) oncology: the first A","volume":"24","author":"Bleyer","year":"2007","journal-title":"Pediatr. Hematol. Oncol."},{"issue":"15_suppl","key":"10.1016\/j.critrevonc.2022.103886_bib6","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2020.38.15_suppl.e13600","article-title":"Epidemiology of adenoid cystic carcinoma in the United States","volume":"38","author":"Boyle","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2022.103886_bib7","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.00747","article-title":"Evolutionary dynamics of cancer in response to targeted combination therapy","volume":"2","author":"Bozic","year":"2013","journal-title":"Elife"},{"issue":"2","key":"10.1016\/j.critrevonc.2022.103886_bib8","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1093\/annonc\/mdu459","article-title":"Rare Cancers Europe (RCE) Consensus Panel. Rare Cancers Europe (RCE) methodological recommendations for clinical studies in rare cancers: a European consensus position paper","volume":"26","author":"Casali","year":"2015","journal-title":"Ann. Oncol."},{"issue":"6","key":"10.1016\/j.critrevonc.2022.103886_bib9","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1093\/annonc\/mdr522","article-title":"A phase II study of sunitinib in recurrent and\/or metastatic adenoid cystic carcinoma (ACC) of the salivary glands: current progress and challenges in evaluating molecularly targeted agents in ACC","volume":"23","author":"Chau","year":"2012","journal-title":"Ann. Oncol."},{"issue":"13","key":"10.1016\/j.critrevonc.2022.103886_bib10","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1200\/JCO.2006.07.3049","article-title":"Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria","volume":"25","author":"Choi","year":"2007","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2022.103886_bib11","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1097\/PRS.0b013e3181df64fa","article-title":"A guide to organizing a multicentre clinical trial","volume":"126","author":"Chung","year":"2010","journal-title":"Plast. Reconstr. Surg."},{"issue":"8","key":"10.1016\/j.critrevonc.2022.103886_bib12","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.oraloncology.2008.10.010","article-title":"Survival from salivary gland adenoid cystic carcinoma in European populations","volume":"45","author":"Ciccolallo","year":"2009","journal-title":"Oral Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2022.103886_bib13","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1001\/archotol.1974.00780040087001","article-title":"Adenoid cystic carcinoma in the head and neck (cylindroma)","volume":"100","author":"Conley","year":"1974","journal-title":"Arch. Otolaryngol."},{"issue":"1","key":"10.1016\/j.critrevonc.2022.103886_bib14","doi-asserted-by":"crossref","DOI":"10.1038\/cti.2014.29","article-title":"Therapeutic DNA vaccination against colorectal cancer by targeting the MYB oncoprotein","volume":"4","author":"Cross","year":"2015","journal-title":"Clin. Transl. Immunol."},{"issue":"8","key":"10.1016\/j.critrevonc.2022.103886_bib15","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1200\/JCO.2007.13.5335","article-title":"Ethical, scientific, and regulatory perspectives regarding the use of placebos in cancer clinical trials","volume":"26","author":"Daugherty","year":"2008","journal-title":"J. Clin. Oncol."},{"issue":"15","key":"10.1016\/j.critrevonc.2022.103886_bib16","doi-asserted-by":"crossref","first-page":"4138","DOI":"10.1158\/1078-0432.CCR-16-2942","article-title":"A phase II study of dovitinib in patients with recurrent or metastatic adenoid cystic carcinoma","volume":"23","author":"Dillon","year":"2017","journal-title":"Clin. Cancer Res."},{"issue":"2","key":"10.1016\/j.critrevonc.2022.103886_bib17","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S1470-2045(19)30691-6","article-title":"Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials","volume":"21","author":"Doebele","year":"2020","journal-title":"Lancet Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2022.103886_bib18","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.critrevonc.2022.103886_bib19","unstructured":"Elevar Therapeutics announces Orphan Drug Designation for Rivoceranib (apatinib) for the treatment of adenoid cystic carcinoma (ACC), News release. February 8, 2021. Accessed January 7, 2022. \u3008https:\/\/bit.ly\/36RCCOET\u3009."},{"key":"10.1016\/j.critrevonc.2022.103886_bib20","series-title":"Considerations for the Inclusion of Adolescent Patients in Adult Oncology Clinical Trials Guidance for Industry","author":"FDA","year":"2019"},{"issue":"17","key":"10.1016\/j.critrevonc.2022.103886_bib21","doi-asserted-by":"crossref","first-page":"4336","DOI":"10.3390\/cancers13174336","article-title":"Centralised RECIST assessment and clinical outcomes with lenvatinib monotherapy in recurrent and metastatic adenoid cystic carcinoma","volume":"13","author":"Feeney","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.critrevonc.2022.103886_bib22","doi-asserted-by":"crossref","unstructured":"Ferrarotto, R., Alpert, G., Gluschnaider, U., Rauch, R., Mondshine, A., Solomon, O., Kramer, B., Izumchenko, E., Heymach, J., Vergara-Silva, A., Aster, J., Davis, M., 2019. AL101 mediated tumor inhibition in Notch mutated ACC PDX models [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res;79(13 Suppl):Abstract nr 4885.","DOI":"10.1158\/1538-7445.AM2019-4885"},{"issue":"suppl 16","key":"10.1016\/j.critrevonc.2022.103886_bib23","article-title":"A phase 2 clinical trial of axitinib and avelumab in patients with recurrent\/metastatic adenoid cystic carcinoma (ACC)","volume":"40","author":"Ferrarotto","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.critrevonc.2022.103886_bib24","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1093\/annonc\/mdy171","article-title":"A phase I dose-escalation and dose-expansion study of brontictuzumab in subjects with selected solid tumors","volume":"29","author":"Ferrarotto","year":"2018","journal-title":"Ann. Oncol."},{"issue":"suppl 16","key":"10.1016\/j.critrevonc.2022.103886_bib25","article-title":"Results of ACCURACY: a phase 2 trial of AL101, a selective gamma secretase inhibitor, in subjects with recurrent\/metastatic (R\/M) adenoid cystic carcinoma (ACC) harboring Notch activating mutations (Notchmut)","volume":"40","author":"Ferrarotto","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2022.103886_bib26","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1200\/JCO.2016.67.5264","article-title":"Activating NOTCH1 mutations define a distinct subgroup of patients with adenoid cystic carcinoma who have poor prognosis, propensity to bone and liver metastasis, and potential responsiveness to Notch1 inhibitors","volume":"35","author":"Ferrarotto","year":"2017","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2022.103886_bib27","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1158\/1078-0432.CCR-20-1192","article-title":"Proteogenomic analysis of salivary adenoid cystic carcinomas defines molecular subtypes and identifies therapeutic targets","volume":"27","author":"Ferrarotto","year":"2021","journal-title":"Clin. Cancer Res."},{"issue":"5","key":"10.1016\/j.critrevonc.2022.103886_bib28","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1111\/his.13281","article-title":"MYB, MYBL1, MYBL2 and NFIB gene alterations and MYC overexpression in salivary gland adenoid cystic carcinoma","volume":"71","author":"Fujii","year":"2017","journal-title":"Histopathology"},{"issue":"24","key":"10.1016\/j.critrevonc.2022.103886_bib29","doi-asserted-by":"crossref","first-page":"12528","DOI":"10.18632\/oncotarget.2985","article-title":"A unifying gene signature for adenoid cystic cancer identifies parallel MYB-dependent and MYB-independent therapeutic targets","volume":"5","author":"Gao","year":"2014","journal-title":"Oncotarget"},{"issue":"17","key":"10.1016\/j.critrevonc.2022.103886_bib30","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1200\/JCO.21.00449","article-title":"Management of salivary gland malignancy: ASCO guideline","volume":"39","author":"Geiger","year":"2021","journal-title":"J. Clin. Oncol."},{"issue":"20","key":"10.1016\/j.critrevonc.2022.103886_bib31","doi-asserted-by":"crossref","first-page":"32918","DOI":"10.18632\/oncotarget.16464","article-title":"A phase 2 study of vorinostat in locally advanced, recurrent, or metastatic adenoid cystic carcinoma","volume":"8","author":"Goncalves","year":"2017","journal-title":"Oncotarget"},{"issue":"4","key":"10.1016\/j.critrevonc.2022.103886_bib32","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.21037\/jtd.2018.03.70","article-title":"Effects of para-toluenesulfonamide intratumoral injection on pulmonary adenoid cystic carcinoma complicating with severe central airway obstruction: a 5-year follow-up study","volume":"10","author":"Guan","year":"2018","journal-title":"J. Thorac. Dis."},{"key":"10.1016\/j.critrevonc.2022.103886_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.oraloncology.2021.105366","article-title":"A phase II trial of all-trans retinoic acid (ATRA) in advanced adenoid cystic carcinoma","volume":"119","author":"Hanna","year":"2021","journal-title":"Oral. Oncol."},{"issue":"17","key":"10.1016\/j.critrevonc.2022.103886_bib34","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1016\/j.ejca.2008.08.014","article-title":"Phase II study on gemcitabine in recurrent and\/or metastatic adenoid cystic carcinoma of the head and neck (EORTC 24982)","volume":"44","author":"van Herpen","year":"2008","journal-title":"Eur. J. Cancer."},{"issue":"10","key":"10.1016\/j.critrevonc.2022.103886_bib35","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1093\/annonc\/mdw287","article-title":"A phase II study of axitinib (AG-013736) in patients with incurable adenoid cystic carcinoma","volume":"27","author":"Ho","year":"2016","journal-title":"Ann. Oncol."},{"issue":"15_suppl","key":"10.1016\/j.critrevonc.2022.103886_bib36","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2016.34.15_suppl.6096","article-title":"Phase II study of regorafenib in progressive, recurrent\/metastatic adenoid cystic carcinoma","volume":"34","author":"Ho","year":"2016","journal-title":"J. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.critrevonc.2022.103886_bib37","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1038\/ng.2643","article-title":"The mutational landscape of adenoid cystic carcinoma","volume":"45","author":"Ho","year":"2013","journal-title":"Nat. Genet."},{"issue":"10","key":"10.1016\/j.critrevonc.2022.103886_bib38","doi-asserted-by":"crossref","first-page":"4276","DOI":"10.1172\/JCI128227","article-title":"Genetic hallmarks of recurrent\/metastatic adenoid cystic carcinoma","volume":"129","author":"Ho","year":"2019","journal-title":"J. Clin. Investig."},{"issue":"4","key":"10.1016\/j.critrevonc.2022.103886_bib39","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/S1470-2045(19)30856-3","article-title":"Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1\/2 clinical trials","volume":"21","author":"Hong","year":"2020","journal-title":"Lancet Oncol."},{"issue":"5","key":"10.1016\/j.critrevonc.2022.103886_bib40","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1002\/hed.23664","article-title":"Efficacy of nelfinavir as monotherapy in refractory adenoid cystic carcinoma: Results of a phase II clinical trial","volume":"37","author":"Hoover","year":"2015","journal-title":"Head Neck"},{"issue":"6","key":"10.1016\/j.critrevonc.2022.103886_bib41","doi-asserted-by":"crossref","first-page":"vi335","DOI":"10.1093\/annonc\/mdw376.24","article-title":"Dovitinib in advanced adenoid cystic carcinoma of the salivary glands: Ontario Clinical Oncology Group DOVE trial","volume":"27","author":"Hotte","year":"2016","journal-title":"Ann. Oncol."},{"issue":"5","key":"10.1016\/j.critrevonc.2022.103886_bib42","doi-asserted-by":"crossref","first-page":"368","DOI":"10.7326\/M20-0104","article-title":"Analysis of response data for assessing treatment effects in comparative clinical studies","volume":"173","author":"Huang","year":"2020","journal-title":"Ann. Intern. Med."},{"issue":"9","key":"10.1016\/j.critrevonc.2022.103886_bib43","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1038\/nrc1913","article-title":"Comparing antibody and small-molecule therapies for cancer","volume":"6","author":"Imai","year":"2006","journal-title":"Nat. Rev. Cancer"},{"issue":"33","key":"10.1016\/j.critrevonc.2022.103886_bib44","doi-asserted-by":"crossref","first-page":"3745","DOI":"10.1200\/JCO.2017.73.4186","article-title":"Re-evaluating eligibility criteria for oncology clinical trials: analysis of investigational new drug applications in 2015","volume":"35","author":"Jin","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2022.103886_bib45","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-21-1061","article-title":"Randomized phase II study of axitinib versus observation in patients with recurred or metastatic adenoid cystic carcinoma","author":"Kang","year":"2021","journal-title":"Clin. Cancer Res."},{"issue":"15","key":"10.1016\/j.critrevonc.2022.103886_bib46","doi-asserted-by":"crossref","first-page":"2612","DOI":"10.1002\/cncr.29401","article-title":"Phase 2 study of dovitinib in patients with metastatic or unresectable adenoid cystic carcinoma","volume":"121","author":"Keam","year":"2015","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2022.103886_bib47","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2407-14-795","article-title":"A multicenter phase II study of everolimus in patients with progressive unresectable adenoid cystic carcinoma","volume":"14","author":"Kim","year":"2014","journal-title":"BMC Cancer"},{"issue":"25","key":"10.1016\/j.critrevonc.2022.103886_bib48","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1200\/JCO.2015.62.1854","article-title":"Modernizing eligibility criteria for molecularly driven trials","volume":"33","author":"Kim","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2022.103886_bib49","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/978-3-030-01207-6_8","article-title":"Orphan drugs in oncology","volume":"213","author":"Korchagina","year":"2019","journal-title":"Recent Results Cancer Res."},{"issue":"7","key":"10.1016\/j.critrevonc.2022.103886_bib50","doi-asserted-by":"crossref","first-page":"2236","DOI":"10.1245\/s10434-013-2911-z","article-title":"Rare breast cancer: 933 adenoid cystic carcinomas from the National Cancer Data Base","volume":"20","author":"Kulkarni","year":"2013","journal-title":"Ann. Surg. Oncol."},{"key":"10.1016\/j.critrevonc.2022.103886_bib51","unstructured":"Lenvima prescribing information FDA, Accessed January 13 2022, Available online at \u3008https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/206947s020lbl.pdf\u3009."},{"issue":"12","key":"10.1016\/j.critrevonc.2022.103886_bib52","doi-asserted-by":"crossref","first-page":"2859","DOI":"10.1158\/1078-0432.CCR-19-3758","article-title":"The immune microenvironment and neoantigen landscape of aggressive salivary gland carcinomas differ by subtype","volume":"26","author":"Linxweiler","year":"2020","journal-title":"Clin. Cancer Res."},{"issue":"9","key":"10.1016\/j.critrevonc.2022.103886_bib53","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1002\/cncr.32754","article-title":"Patients with adenoid cystic carcinomas of the salivary glands treated with lenvatinib: activity and quality of life","volume":"126","author":"Locati","year":"2020","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2022.103886_bib54","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.ejca.2016.09.022","article-title":"A phase II study of sorafenib in recurrent and\/or metastatic salivary gland carcinomas: translational analyses and clinical impact","volume":"69","author":"Locati","year":"2016","journal-title":"Eur. J. Cancer"},{"issue":"1","key":"10.1016\/j.critrevonc.2022.103886_bib55","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.ijrobp.2020.08.018","article-title":"A randomized phase 2 study of pembrolizumab with or without radiation in patients with recurrent or metastatic adenoid cystic carcinoma","volume":"109","author":"Mahmood","year":"2021","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"10","key":"10.1016\/j.critrevonc.2022.103886_bib56","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1084\/jem.20180939","article-title":"Zebrafish blastomere screen identifies retinoic acid suppression of MYB in adenoid cystic carcinoma","volume":"215","author":"Mandelbaum","year":"2018","journal-title":"J. Exp. Med."},{"issue":"9","key":"10.1016\/j.critrevonc.2022.103886_bib57","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1093\/annonc\/mdq051","article-title":"Change in lung tumor volume as a biomarker of treatment response: a critical review of the evidence","volume":"21","author":"Mozley","year":"2010","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2022.103886_bib58","unstructured":"NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) - Head and Neck Cancers. Version 2.2022 \u2014 April 26, 2022. Available at: \u3008https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/head-and-neck.pdf\u3009."},{"key":"10.1016\/j.critrevonc.2022.103886_bib59","series-title":"Public Law 97-414","author":"Orphan Drug Act","year":"1983"},{"issue":"44","key":"10.1016\/j.critrevonc.2022.103886_bib60","doi-asserted-by":"crossref","first-page":"18740","DOI":"10.1073\/pnas.0909114106","article-title":"Recurrent fusion of MYB and NFIB transcription factor genes in carcinomas of the breast and head and neck","volume":"106","author":"Persson","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"1","key":"10.1016\/j.critrevonc.2022.103886_bib61","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.oraloncology.2005.12.026","article-title":"A phase II study of Imatinib for advanced adenoid cystic carcinoma of head and neck salivary glands","volume":"43","author":"Pfeffer","year":"2007","journal-title":"Oral Oncol."},{"key":"10.1016\/j.critrevonc.2022.103886_bib62","doi-asserted-by":"crossref","DOI":"10.1016\/j.conctc.2019.100409","article-title":"First-in-human phase I clinical trial of a combined immune modulatory approach using TetMYB vaccine and Anti-PD-1 antibody in patients with advanced solid cancer including colorectal or adenoid cystic carcinoma: the MYPHISMO study protocol (NCT03287427)","volume":"16","author":"Pham","year":"2019","journal-title":"Contemp. Clin. Trials Commun."},{"issue":"19","key":"10.1016\/j.critrevonc.2022.103886_bib63","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1001\/archinternmed.2009.306","article-title":"Reporting of safety results in published reports of randomized controlled trials","volume":"169","author":"Pitrou","year":"2009","journal-title":"Arch. Intern. Med."},{"issue":"29","key":"10.1016\/j.critrevonc.2022.103886_bib64","doi-asserted-by":"crossref","first-page":"4507","DOI":"10.1200\/JCO.2010.30.2307","article-title":"Phase I study of vorinostat in patients with advanced solid tumors and hepatic dysfunction: a National Cancer Institute Organ Dysfunction Working Group study","volume":"28","author":"Ramalingam","year":"2010","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2022.103886_bib65","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1080\/10543406.2014.920856","article-title":"Comparison of single-arm vs. randomized phase II clinical trials: a Bayesian approach","volume":"25","author":"Sambucini","year":"2015","journal-title":"J. Biopharm. Stat."},{"key":"10.1016\/j.critrevonc.2022.103886_bib66","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/1741-7015-8-18","article-title":"CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials","volume":"8","author":"Schulz","year":"2010","journal-title":"BMC Med."},{"key":"10.1016\/j.critrevonc.2022.103886_bib67","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.phrs.2017.07.013","article-title":"Drug repurposing in cancer","volume":"124","author":"Sleire","year":"2017","journal-title":"Pharm. Res."},{"issue":"18","key":"10.1016\/j.critrevonc.2022.103886_bib68","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1200\/JCO.18.01859","article-title":"Phase II study of lenvatinib in patients with progressive, recurrent or metastatic adenoid cystic carcinoma","volume":"37","author":"Tchekmedyian","year":"2019","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2022.103886_bib69","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1002\/hed.23577","article-title":"Phase II trial of sorafenib in advanced salivary adenoid cystic carcinoma of the head and neck","volume":"37","author":"Thomson","year":"2015","journal-title":"Head Neck"},{"key":"10.1016\/j.critrevonc.2022.103886_bib70","unstructured":"U.S Food and Drug Administration orphan drug database, Accessed on 12\/01\/2022 - available at \u3008https:\/\/www.accessdata.fda.gov\/scripts\/opdlisting\/oopd\/detailedIndex.cfm?cfgridkey=388012\u3009."},{"issue":"8","key":"10.1016\/j.critrevonc.2022.103886_bib71","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1002\/hed.10126","article-title":"Distant metastases of adenoid cystic carcinoma of the salivary glands and the value of diagnostic examinations during follow-up","volume":"24","author":"van der Wal","year":"2002","journal-title":"Head Neck"},{"issue":"15_suppl","key":"10.1016\/j.critrevonc.2022.103886_bib72","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2021.39.15_suppl.6026","article-title":"Preliminary results of the efficacy and safety of all-trans retinoic acid combined with low-dose apatinib in the treatment of patients with recurrent\/metastatic adenoid cystic carcinoma of the head and neck","volume":"39","author":"Ye","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2022.103886_bib73","doi-asserted-by":"crossref","DOI":"10.1177\/17588359211013626","article-title":"Apatinib in patients with recurrent or metastatic adenoid cystic carcinoma of the head and neck: a single-arm, phase II prospective study","volume":"13","author":"Zhu","year":"2021","journal-title":"Ther. Adv. Med. Oncol."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842822003109?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842822003109?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T19:45:46Z","timestamp":1760903146000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842822003109"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":73,"alternative-id":["S1040842822003109"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2022.103886","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Drug-based therapy for advanced adenoid cystic carcinoma: Current landscape and challenges based on an overview of registered clinical trials","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2022.103886","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"103886"}}